HAEMONETICS CORP (HAE)
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Haemonetics Corporation
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 121.16 | 123.75 | 116.79 | 119.93 | 834,677 |
| Nov 5, 2026 | 126.06 | 132.00 | 121.22 | 124.11 | 1,302,144 |
| Nov 4, 2026 | 122.16 | 128.82 | 121.26 | 127.42 | 982,030 |
| Nov 3, 2026 | 119.07 | 121.44 | 119.00 | 120.28 | 834,603 |
| Nov 2, 2026 | 120.36 | 121.48 | 119.08 | 120.14 | 678,589 |
| Oct 30, 2026 | 120.50 | 120.50 | 118.39 | 119.65 | 453,354 |
| Oct 29, 2026 | 118.85 | 120.54 | 117.97 | 119.79 | 558,543 |
| Oct 28, 2026 | 119.40 | 120.79 | 117.71 | 118.32 | 501,823 |
| Oct 27, 2026 | 118.69 | 121.91 | 117.70 | 119.97 | 900,886 |
| Oct 26, 2026 | 118.62 | 119.43 | 117.49 | 119.19 | 469,738 |
| Oct 23, 2026 | 115.50 | 119.20 | 115.49 | 118.51 | 777,378 |
| Oct 22, 2026 | 117.70 | 118.68 | 116.07 | 116.16 | 365,126 |
| Oct 21, 2026 | 117.49 | 119.14 | 116.65 | 117.11 | 843,472 |
| Oct 20, 2026 | 119.50 | 120.50 | 117.20 | 118.21 | 585,003 |
| Oct 19, 2026 | 118.07 | 119.82 | 117.00 | 118.73 | 392,222 |
| Oct 16, 2026 | 121.83 | 121.84 | 118.19 | 118.28 | 471,522 |
| Oct 15, 2026 | 122.20 | 122.46 | 118.65 | 121.29 | 747,648 |
| Oct 14, 2026 | 121.81 | 122.53 | 119.55 | 121.11 | 592,145 |
| Oct 13, 2026 | 122.80 | 123.77 | 121.05 | 121.72 | 829,194 |
| Oct 12, 2026 | 118.70 | 122.24 | 118.36 | 122.06 | 895,092 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| EVP, Chief Commercial Officer | Automatic Sell | 146 | $17.5K | Oct 30, 2026 | |
| Director | Grant/Award | 2.5K | -- | Jul 24, 2026 | |
| Director | Grant/Award | 2.5K | -- | Jul 24, 2026 | |
| Director | Grant/Award | 2.5K | -- | Jul 24, 2026 | |
| Director | Grant/Award | 2.5K | -- | Jul 24, 2026 | |
| Director | Grant/Award | 2.5K | -- | Jul 24, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jan 2024 | 6.1M | 13.3% | 13G |
BlackRock, Inc. | 5.9M | 13.0% | 13F |
Neuberger Berman Group LLC | 4.2M | 9.2% | 13F |
Neuberger Berman Group LLC 61-1591182 · also on 13F· may incl. warrants· filed Feb 2024 | 3.5M | 7.8% | 13G |
AQR Capital Management, LLC · also on 13F· may incl. warrants· filed Feb 2026 | 3.2M | 6.9% | 13G |
VANGUARD PORTFOLIO MANAGEMENT LLC | 2.5M | 5.6% | 13F |
AQR CAPITAL MANAGEMENT LLC | 2.3M | 5.0% | 13F |
Wellington Management Group LLP · filed Aug 2025 | 2.2M | 4.8% | 13G |
T. Rowe Price Investment Management, Inc. · also on 13F· may incl. warrants· filed May 2025 | 2.2M | 4.8% | 13G |
ARIEL INVESTMENTS, LLC | 2.1M | 4.5% | 13F |
Insiders
- Galvin RoyEVP, Chief Commercial Officer
- KROLL MARK WDirector
- Johnson Lloyd EmersonDirector
- ABERNATHY ROBERT EDirector
- Zane Ellen MDirector
- Madaus Martin DDirector
- Pomeroy ClaireDirector
- Bryant Diane MDirector
- COYLE MICHAEL JDirector
- Miller Laurie A.SVP, Human Resources
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions.
It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage.
Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions.
Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations.
The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
13F filers report 48.63M shares, more than the 45.54M outstanding, so no percentage is shown. 13F reports lag by a quarter and shares lent to short sellers can be counted twice.
30d Avg
700.76K
60d Avg
699.86K
90d Avg
715.42K